Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Complete Title: Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Trial Phase: N/A
Investigator: Gabriela Chiorean
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.
Keywords:
- Bladder Cancer
- Esophageal Cancer
- Gastric Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Thyroid Cancer
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Glioblastoma
- Colorectal Neoplasms
- Carcinoma, Hepatocellular
- Cholangiocarcinoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
N/A
Gabriela Chiorean
RG1121312
NCT04566393
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Bladder Cancer
Esophageal Cancer
Gastric Cancer
Head and Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Thyroid Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Glioblastoma
Colorectal Neoplasms
Carcinoma, Hepatocellular
Cholangiocarcinoma